Understanding Pine Bark Extract as an Alternative Treatment (UPBEAT) Study

Not Recruiting

Trial ID: NCT00425945

Age - 18 Years-N/A Gender - All Accepting Healthy Volunteers - yes

Purpose

The purpose of this study is to investigate the efficacy of Flavangenol® (Toyo Shinyaku, Japan), a pine bark extract, in lowering blood pressure and improving glycemic control and plasma lipoprotein profile.

Official Title

Cardiovascular Effects of Pine Bark Extract

Stanford Investigator(s)

Randall Stafford
Randall Stafford

Professor of Medicine (Stanford Center for Research in Disease Prevention)

Eligibility


Inclusion Criteria:

   - Systolic blood pressure between 125 and 159 mmHg and diastolic blood pressure (DBP) <
   100 mmHg

   - Body mass index (BMI) 25.0-34.9

   - Triglycerides (TG) < 450 mg/dL

   - Low Density Lipoprotein (LDL) < 200 mg/dL

   - Fasting blood glucose (FBG) < 126 mg/dL

Exclusion Criteria:

   - DBP > 95 mmHg

   - LDL > 170 mg/dL

   - TG > 300 mg/dL

   - FBG > 110 mg/dL

View More
View Less

Intervention(s):

drug: Pine Bark Extract (Flavangenol®)

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Rebbeca Drieling
6507236528

©2024 Stanford Medicine